Becton Dickinson (BDX)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$184.74-1.54%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · BDX
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $185 BDX trades at 14× p/e, below its 28× p/e peer median, but our blended $182 fair value is roughly in line with the price. We hold it with medium confidence: the peer anchor overstates how cheap it looks. Analysts target $180–$210. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $190.00 | — | — | Analyst | high |
| dcf fcff | 12M | $340.73 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $68.60 | — | — | TTM | high |
| graham number | 12M | $161.10 | — | — | TTM | high |
| Peer EV/EBITDA |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$180.00 – $210.00 (median $190.00) · 7 analysts · as of 2026-08-13
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Richer than its own typical valuation.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $33.75 |
| 6.2 |
| 14.93 |
| TTM |
| high |
| Peer P/FCF | 12M | $233.41 | 24.6 | 9.47 | TTM | high |
| Peer P/E | 12M | $247.90 | 18.7 | 13.25 | ntm analyst | high |
| Peer P/S | 12M | $239.79 | 2.9 | 81.46 | TTM | high |
| PEG | 12M | $127.10 | 9.8 | 13.00 | TTM | high |
| residual income | 12M | $108.86 | — | — | TTM | high |
| Own P/E history | 12M | $165.00 | 12.7 | 13.00 | TTM | high |
| triangulated | 12M | $383.53 | 28.3 | 13.57 | Triangulated | high |
| Peer P/FCF | 3Y | $349.58 | 24.6 | 14.18 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $107.61 | 18.7 | 5.75 | Analyst | medium |
| PEG | 3Y | $56.22 | 9.8 | 5.75 | Analyst | medium |
| Own P/E history | 3Y | $72.99 | 12.7 | 5.75 | Analyst | medium |
| Peer P/FCF | 5Y | $457.61 | 24.6 | 18.57 | Hist. CAGR(prov.) | medium |